ATHEROSCLEROTIC PROGRESSION/ REGRESSION
|
|
|
Atherosclerotic Progression/ Regression
|
|
|
Lp(a): Vascular Events by Sex and Quintile at Baseline (Cardiovascular Health Study)
|
CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients
|
ASAP: Study Design
|
ASAP: Cholesterol-Lowering Results
|
ASAP: Primary Parameter Change in Overall Carotid IMT
|
EPAT: Baseline Characteristics of Evaluable Patients
|
EPAT: Progression of Carotid Artery Intima-Media Thickness (IMT)
|
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
|
ASTEROID: High-Dose Statin Therapy–Effects on Atherosclerosis
|
ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C
|
ASTEROID: High-Dose Statin Therapy—Effects on Discrete Coronary Stenoses
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Primary Endpoint
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Secondary Endpoints
|
ENHANCE: Combination Therapy—Primary Outcome
|
ENHANCE: Combination Therapy—Effects on Lipoproteins
|
SANDS: Study Design
|
SANDS: Change in CIMT with Aggressive vs Standard Therapy
|
PERISCOPE: Study Design
|
PERISCOPE: Change in PAV
|
LCAS: Effect on Lipids between Baseline and End of Trial
|
LCAS: Primary End Point
|
LCAS: Effect of Treatment on Patients Experiencing Progression or Regression
|
LCAS: Conclusions
|
L-CAD: Comparison of End Points, Change in Lumen Diameters
|
HATS: Lipid Levels Before and During Treatment
|
HATS: Percent Change in Stenosis
|
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
|
IBIS-2: Effects of Lp-PLA2 Inhibitor Darapladib on Coronary Atherosclerotic Plaque
|
IBIS-2: Decreases in Progression of Necrotic Core
|
PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis
|
PDAY: Prevalence of lesions in LAD
|
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
|
Post-CABG Study: Aggressive vs Moderate Treatment
|
Post-CABG: End Points, Results, Conclusions
|
Post-CABG Angiographic Outcomes
|
Post-CABG: Event Rates by Cholesterol Group
|
Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors
|
PROactive: Time to Secondary Endpoint (Death, Nonfatal MI, Stroke)
|
REVERSAL: Effect of Moderate vs Intensive Statin Therapy
|
Post-CABG: Effect of Aggressive Lipid Lowering on a Subgroup of Patients With Diabetes
|
ORION: Study Design
|
Effect of Lifestyle Changes on Angiographic CAD
|
Lp(a) in Atherogenesis: Another Culprit?
|
Homocysteine: Role of Atherogenesis
|
Continuum of Patients at Risk for a CHD Event
|
Coronary Artery Calcification (CAC) and CHD Family History
|
Ethnic Disparities in CVD Risk Factors in the US Population
|
US Death Rates From CVD by Ethnicity and Sex, 1980-2001
|
Smoking-Related CV Mortality in Year 2000
|
Trends in Total Cholesterol for US Adults, 1960-1962 to 1999-2002
|
WISE Study: Review of Ischemic Heart Disease in Women
|
Treatment Options for Peripheral Arterial Disease
|
Treatment Options for Peripheral Arterial Disease (cont)
|
Trans-Fatty Acid Intake and Relative Risk for CHD
|
4S: Effect of Cholesterol Lowering on Noncoronary Ischemic Symptoms and Angina
|
Lipid Lowering and Plaque Regression: Monotherapy Studies
|
Event Reduction in Angiographic Plaque Regression Trials
|
Endothelial Dysfunction: A Barometer of Cardiovascular Risk?
|
Association Between Change in Lumen Size and Coronary Events: Important Factors
|
Effects of Lipid-Lowering Therapy on Endothelial Function in CHD Patients
|
Effect of Cholesterol Lowering on Myocardial Ischemia
|
Atherosclerosis: A Progressive Process
|
The Anatomy of Atherosclerotic Plaque
|
Angiographically Inapparent Atheroma
|
The Matrix Skeleton of Unstable Coronary Artery Plaque
|
Histologic Stain of Plaque
|
Characteristics of Plaques Prone to Rupture
|
Updated Model of Lipoprotein Metabolism and Reverse Cholesterol Transport
|
TGs Predict CAD Risk Independently of TC and HDL-C
|
Hypertriglyceridemia and CHD Risk: Associated Abnormalities
|
Association of Small, Dense LDL With Myocardial Infarction
|
Responses to a 75-g Oral Glucose Challenge in Relation to LDL Particle Diameter
|
Characteristics of LDL Phenotype B
|
Cumulative Distribution of Adjusted Plasma TG Levels: LDL Phenotypes A and B
|
Cumulative Distribution of Adjusted HDL-C: LDL Phenotypes A and B
|
Interrelation Between Atherosclerosis and Insulin Resistance
|
Composite CIMT With Metabolic Syndrome in Young Adults
|
Progression to Atherosclerotic Clinical Events in Patients With Diabetes
|
Atherosclerosis in Diabetes
|
Insulin Resistance and Atherosclerosis: Posited Relationships
|
Significance of Small, Dense LDL
|
Effects of Atorvastatin on CRP and Endothelial Function in Type 2 Diabetes
|
Relation Between Change in CRP Endothelium-Dependent Vasodilation With Atorvastatin in Type 2 Diabetes (6 Months)
|
Effects of Lipid Lowering on Endothelial Function: Hypercholesterolemic Patients
|
Effects of Lipid-Lowering Therapy on Myocardial Perfusion in CHD Patients
|
Lowest Effective Aspirin Dose for MI and Stroke Reduction
|
Metabolic Syndrome and 10-Year CVD Risk
|
Potential Mechanisms of Atherogenesis in Diabetes
|
Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (1 of 2)
|
Impact of Statin-Induced Changes in LDL-C and HDL-C on Atheroma Burden (2 of 2)
|
Association of Subclinical Atherosclerosis Outcomes With 10-Year FRS
|
CAC Cutoffs by 10-Year CHD Event Risk Among CVD-Free Subjectsa
|
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C
|
CVD Event Prediction Among Subjects With Subclinical Atherosclerosis and Low HDL-C: 5-Year Follow-Up
|
Use of CRP to Assess CVD Risk Across Age Groups: Study Design
|
Effect of Statins on Atherosclerosis After ACS: Design
|
Effect of Statins on Atherosclerosis After ACS: Percent Change in Atheroma Volume
|
Intensive Lifestyle Interventions: Effects on Endothelial Function and Inflammatory Markers Design
|
Intensive Lifestyle Interventions: Effects on Endothelial Function and Inflammatory Markers Results
|
|
|
CLINICAL GUIDELINES
|
|
|
ATP III
|
|
|
ATP III: CHD Risk Equivalents
|
SEACOAST: Combination Therapy for Increased Non–HDL-C
Primary Endpoint
|
ATP III: Features Shared With ATP II
|
ATP III: LDL-C, HDL-C, TC Classification
|
ATP III: Major CHD Risk Factors Other Than LDL-C
|
ATP III: Additional CHD Risk Factors
|
ATP III: Assessment of Risk
|
ATP III: Risk Categories, LDL-C Goals
|
ATP III: CHD Risk Equivalents
|
ATP III: LDL-C Treatment Cutpoints for Therapy
|
ATP III: Nutritional Components of the TLC Diet
|
ATP III: Additional Dietary Options for LDL-C Lowering
|
ATP III: Management of Elevated TG
|
ATP III: The Metabolic Syndrome
|
ATP III: Management of Diabetic Dyslipidemia
|
ATP III: LDL-C Measurements in Patients Hospitalized for Major Coronary Events
|
ATP III: Special Populations—Women, Middle-Aged Men
|
ATP III: Improving Adherence—Focus on the Patient
|
ATP III: Improving Adherence—Focus on the Physician, Delivery System
|
ATP III Framingham Risk Scoring–Assessing CHD Risk in Men
|
ATP III Framingham Risk Scoring–Assessing CHD Risk in Women
|
ATP III Framingham Risk Scoring–Step 1: Age
|
ATP III Framingham Risk Scoring–Step 2: Total Cholesterol
|
ATP III Framingham Risk Scoring–Step 3: HDL-Cholesterol
|
ATP III Framingham Risk Scoring–Step 4: Systolic Blood Pressure
|
ATP III Framingham Risk Scoring–Step 5: Smoking Status
|
ATP III Framingham Risk Scoring Step 6: Adding Up the Points (Sum From Steps 1–5)
|
ATP III Framingham Risk Scoring–Step 7: CHD Risk for Women
|
ATP III Framingham Risk Scoring Step 7: CHD Risk for Men
|
Update to ATP III Guidelines: Rationale
|
Update to ATP III Guidelines: Rationale (cont'd)
|
ATP III: Updated LDL-C Goals, Treatment Cutpoints
|
ATP III: Updated LDL-C Goals, Treatment Cutpoints (cont'd)
|
Eligible Primary-Prevention Patients by Age and Treatment Scenario (ATP III vs ATP II)
|
ATP III: Management of Very High LDL-C
|
ATP III: Management of Low HDL-C
|
ATP III: Special Populations—Older Adults, Younger Adults
|
ATP III vs ATP II: Increases in Treatment-Eligible Primary-Prevention Patients
|
NHANES Extrapolation: Population Meeting JUPITER Study Eligibility
|
Population Estimatesa at ATP III Risk Categories with CRP ≥2 mg/L
|
Other
|
|
|
AHA Evidence-Based Guidelines for CVD Prevention in Women (cont'd)
|
Cost of CHD in the United States
|
Cost of CVD and Stroke in the United States
|
US Cost of Health Expenditures, Lost Productivity of CVD and Stroke
|
JNC 7: Treatment Algorithm for Hypertension
|
AHA/CDC Panel: Recommendations for Use of hs-CRP in Clinical Practice
|
AHA/CDC Panel: Recommendations for hs-CRP Laboratory Testing
|
Prevalence of Class 3 Obesity in the United States: BRFSS 2000
|
BMI: Adjusted Odds Ratios for Unstable Coronary Artery Disease
|
AHA Get With the Guidelines: Adherence to Treatment Measures
|
AHA Evidence-Based Guidelines for CVD Prevention in Women
|
CV Mortality Risk With NCEP-MetS vs WHO-MetS
|
Updated Criteria for Clinical Diagnosis of Metabolic Syndrome
|
Statin Advisory: Definitions of Muscle Toxicity
|
Statin Advisory: Monitoring Parameters, Follow-Up Schedule
|
Statin Advisory: Clinical Precautions When Prescribing Statin Therapy
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
Statin Advisory: Conclusions
|
ADA: Glycemic Control, BP, and Lipid Targets in Type 2 Diabetes
|
ADA: Treatment Decisions by LDL-C Levels in Adults With Type 2 Diabetes
|
Overview: Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)
|
Consensus Recommendations for Lp-PLA2 Testing
|
NHANES Extrapolation: Population Meeting JUPITER Study Eligibility
|
Population Estimatesa at ATP III Risk Categories with CRP ≥2 mg/L
|
Use of CRP to Assess CVD Risk Across Age Groups: Study Design
|
AHA 2010 Heart Disease and Stroke Statistics: Prevalence and Cost
|
AHA 2010 Heart Disease and Stroke Statistics: Incidence
|
AHA 2010 Heart Disease and Stroke Statistics: Mortality
|
|
|
CLINICAL TRIALS
|
|
|
A-F
|
|
|
Lp(a): An Independent CHD Risk Factor in Men of the Framingham Offspring Cohort
|
Lp(a): Vascular Events by Sex and Quintile at Baseline (Cardiovascular Health Study)
|
AFCAPS/TexCAPS: RR of Acute Coronary Events—LDL-C and Homocysteine
|
AFCAPS/TexCAPS: RR of Acute Coronary Events—TC: HDL-C Ratio and CRP Level
|
AFCAPS/TexCAPS: Effects of LDL C Lowering in Patients With Average Cholesterol Levels
|
ACCESS: Change in LDL-C, Non–HDL-C in All Patients at 54 Weeks
|
4S: Effect of LDL-C Lowering on Coronary Events in Secondary Prevention Trial in Men and Women
|
4S: Findings From a Post Hoc Analysis
|
4S: Lipid Lowering Reduces CHD Event Rates in >65-Year Old Subjects
|
4S: Impact of Drug Therapy on Lipids and Lipoproteins in Older Adults With Hypercholesterolemia
|
4S: Reduction in Coronary Events and Revascularizations in Older Adults With Established CHD
|
4S: Survival of Major Coronary Events in Older Adults
|
4S: Clinical and Economic Benefits of Treatment Over 5-Yr Period
|
CARE: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
|
CARE: Fatal CHD or Nonfatal MI (Primary End Point)
|
CARE: Secondary End Points
|
CARE: Findings From a Post Hoc Analysis
|
CARE: Impact of Drug Therapy on Lipids and Lipoproteins in Older Patients With MI
|
CARE: Reduction in Coronary Events, Revascularizations, and Stroke in Older Adults With MI and Average Cholesterol Levels
|
CARE: Incidence of Coronary Events in Younger Versus Older Patients
|
AFCAPS/TexCAPS: Primary End Point Event Rates Within Demographic and Risk Factor Subgroups
|
A to Z Trial: Primary End Point
|
A to Z Trial: Secondary End Points and Adverse Events
|
CHARISMA: Clopidogrel + Aspirin vs Aspirin Alone in High-Risk CVD Patients
|
Impact of TG Levels on Relative Risk of CHD: Framingham Heart Study
|
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
|
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
|
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
|
Diabetes Prevention Program: Study Design
|
Diabetes Prevention Program
|
The CURVES Trial: A Comparison of LDL-C Lowering Among Statins
|
The CURVES Trial: Comparative LDL-C Reductions
|
ASAP: Study Design
|
ASAP: Cholesterol-Lowering Results
|
ASAP: Primary Parameter Change in Overall Carotid IMT
|
EPAT: Baseline Characteristics of Evaluable Patients
|
EPAT: Progression of Carotid Artery Intima-Media Thickness (IMT)
|
AVERT: Study Design and Inclusion Criteria
|
AVERT: Major Exclusion Criteria
|
AVERT: Overview of Study Procedures
|
AVERT: Primary Efficacy Assessment
|
AVERT: Secondary Efficacy Assessments
|
AVERT: Baseline Patient Characteristics
|
AVERT: Ischemic Events
|
AVERT: Ischemic Events
|
AVERT: Time to First Ischemic Event
|
AVERT: Summary of Lipid Parameters
|
AVERT: Incidence of First Ischemic Event by Time
|
AVERT: Safety Evaluation
|
AVERT: Conclusions
|
ALLHAT-LLT: All-Cause Mortality
|
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
|
ASCOT–LLA: Study Design
|
ASCOT-LLA: Primary End Point
|
ASCOT-LLA: Primary End Point in Subgroups
|
ASCOT-LLA: Secondary End Points
|
ASCOT-LLA: Effect of Atorvastatin vs Placebo on CV and Coronary End Points
|
FIELD: Fenofibrate Effect on Lipids
|
DAIS: Impact of Aggressive Therapy on Atherosclerosis in Patients With Type 2 Diabetes
|
DAIS: Mean Baseline Lipoprotein Levels
|
DAIS: Interim Lipid Results in Patients With Type 2 Diabetes
|
DAIS: Final Results in Patients With Types 2 Diabetes
|
Framingham Heart Study 30-Year Follow-Up: CVD Events in Patients With Diabetes (Ages 35-64)
|
Abnormal Lipid Levels in Men With Type 2 Diabetes
|
Abnormal Lipid Levels in Women With Type 2 Diabetes
|
Secondary Prevention: CHD Risk Reduction in the 4S Subgroup of Patients WIth Diabetes
|
4S: Total Mortality Reduction in a Subgroup of Patients With Diabetes
|
4S: Major CHD Event Reduction in a Subgroup of Patients With Diabetes
|
4S: Treatment Benefit in Subgroup With Impaired Fasting Glucose (FG 110-125 mg/dL)
|
CARE: Reduction of Coronary Events in Patients With Diabetes
|
CARE: Major Coronary Events in the Diabetic Subgroup
|
ARIC: CHD Events, CVD Mortality With/Without MI or Diabetes
|
Collaborative Atorvastatin Diabetes Study (CARDS): Results Summary
|
Collaborative Atorvastatin Diabetes Study (CARDS): Major CVD Events
|
CARDS: Effect of Treatment on Primary and Secondary End Points
|
ASTEROID: High-Dose Statin Therapy–Effects on Atherosclerosis
|
CARDS: Effect of Treatment on Primary End Point by Lipid Level
|
ASTEROID: High-Dose Statin Therapy—Effects on LDL-C and HDL-C
|
ASTEROID: High-Dose Statin Therapy—Effects on Discrete Coronary Stenoses
|
ENHANCE: Combination Therapy—Primary Outcome
|
ENHANCE: Combination Therapy—Effects on Lipoproteins
|
ACCORD: Study Design
|
ACCORD: A1c Levels, Hypoglycemia, and Weight Gain
|
ACCORD: Death from Any Cause
|
ACCORD: Results
|
ADVANCE: Study Design
|
ADVANCE: A1c Levels, Hypoglycemia, and End-Study Weight
|
ADVANCE: Primary Endpoints
|
ADVANCE: Death from Any Cause
|
DIACOR Substudy: Effects of Simvastatin and/or Fenofibrate on Lipoprotein Subparticles
|
DIACOR Substudy: Level of LDL Pattern B at Baseline and Week 12
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
|
ACCORD BP: Effects of Intensive BP_Control on Type 2 Diabetes
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Results
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Additional Results at Year 1
|
Effect of Statins on Atherosclerosis After ACS: Design
|
Effect of Statins on Atherosclerosis After ACS: Percent Change in Atheroma Volume
|
Omega-3 Acid Ethyl Esters in Addition to Statin Therapy: Effects on Lipoprotein Particle Concentrations
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Design
|
ARBITER--6 HALTS: Effect of Niacin ER or Ezetimibe on CIMT
|
Results from ARBITER 6--HALTS: Effect of Niacin ER or Ezetimibe on CIMT
|
Use of CAC Score for CHD Prediction: Results
|
ARBITER 6–Halts: Methods and Final Results
|
ARBITER 6–HALTS: Final Results
|
G-L
|
|
|
LRC Follow-up Study: CVD Mortality by Non–HDL-C and LDL-C in Men
|
LRC Follow-up Study: CVD Mortality by Non-HDL-C and LDL-C in Women
|
L-TAP: Majority of Patients With CHD Do Not Reach NCEP LDL-C Targets
|
L-TAP: Majority of High-Risk Patients Without CHD Do Not Reach NCEP LDL-C Targets
|
L-TAP: Patient Success in Achieving Target LDL-C Levels
|
Lyon Diet Heart Study: Cumulative Survival Without Cardiac Death and Nonfatal MI
|
LIPID: Effect of Lipid Lowering on Lipid Values and Coronary Events in CHD Patients With Average Cholesterol
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Sex
|
LIPID: Reduction in Nonfatal MI and CHD Death Risk Stratified by Diabetic Status
|
LIPID: Reduction in nonfatal MI and CHD Death Risk Stratified by Prerandomization Age
|
LIPID Trial Follow-Up: Cardiovascular Events Over 8 Years
|
LIPID Trial Follow-Up: Serious Adverse Events Over 8 Years
|
LCAS: Effect on Lipids between Baseline and End of Trial
|
LCAS: Primary End Point
|
LCAS: Effect of Treatment on Patients Experiencing Progression or Regression
|
LCAS: Conclusions
|
Heart Protection Study (HPS): Elibigility
|
HPS: Design and Interventions
|
HPS: End Points for Lipid Lowering
|
HPS: Effects of Simvastatin on Cause-Specific Mortality
|
HPS: Effects of Simvastatin on First major Vascular Event
|
HPS: Effects of Simvastatin on Vascular Events by Year
|
HPS: Effects of Simvastatin on Vascular Events by LDL-C
|
HPS: Absolute Risk Reductions
|
Heart Protection Study (HPS): End Points for Antioxidant Vitamin Supplementation
|
HPS: Effects of Antioxidant Vitamins on Cause-Specific Mortality
|
HPS: Effects of Antioxidant Vitamins on First Major Vascular Event
|
HPS: Effects of Antioxidant Vitamins on Vascular Events by Year
|
HPS: Effects of Antioxidant Vitamins on Vascular Events by LDL-C
|
Fasting TG and Risk for CHD: Helsinki Heart Study
|
HIT: Favorable Effects of Fibrate on CVD Events in CHD Patients With Isolated Low HDL-C
|
HERS: Combined HRT Does Not Decrease All-Cause Mortality
|
HERS: Primary CHD Events
|
HERS: HDL-C Distribution in a Cohort With CHD
|
HERS, HERS II: Relative Hazard of CHD Events
|
L-CAD: Effect of Intensive Therapy Post-ACS on Lipid Values
|
L-CAD: Comparison of End Points, Change in Lumen Diameters
|
HATS: Lipid Levels Before and During Treatment
|
HATS: Percent Change in Stenosis
|
IDEAL Study: Secondary End Points
|
IDEAL Study: Effect of Treatment on LDL-C
|
Primary CHD Prevention in Patients With Type 2 Diabetes: The Helsinki Heart Study
|
HPS Substudy: First Major Vascular Event and Patients With Diabetes
|
HPS Substudy: First Major Coronary Event and Stroke by Prior to Diabetes Status
|
HPS Substudy: First Major Vascular Event by LDL-C and Prior Diabetes Status
|
HPS Diabetes Substudy: Absolute Effects on 5-Year Rates of First Major Vascular Event
|
HERS: Risk of Cerebrovascular Disease Events
|
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Participant Profile
|
IBIS-2: Effects of Lp-PLA2 Inhibitor Darapladib on Coronary Atherosclerotic Plaque
|
IBIS-2: Decreases in Progression of Necrotic Core
|
JELIS: Study Design
|
JELIS: Multiple Risk Factorsa and Incidence of Major Coronary Events
|
JELIS: Effects of EPA on Major Coronary Events in Subjects With High TG/Low HDL-C
|
JPAD: Study Design
|
JPAD Results: Primary Endpoint (CVD Composite)
|
JPAD Results: Primary Endpoint in Subgroups
|
JUPITER: Study Design
|
JUPITER: Lipid and Hs-CRP Levels
|
JUPITER Results: Primary Endpoint
|
JUPITER Results: Components of Primary Endpoint
|
JUPITER Results: Summary
|
PROactive: Time to Secondary Endpoint (Death, Nonfatal MI, Stroke)
|
NHANES Extrapolation: Population Meeting JUPITER Study Eligibility
|
Population Estimatesa at ATP III Risk Categories with CRP ≥2 mg/L
|
JUPITER Statin Use for Primary Prevention of CVD Events in Women
|
Meta-Analysis: Statin Use for Primary Prevention of CVD Events in Women
|
M-R
|
|
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Primary Endpoint
|
METEOR: Effects of Statin Therapy on Low-Risk Patients—Secondary Endpoints
|
NOMAS: Study Design
|
NOMAS: Event-Free Curves Based on MetSyn and Endothelial Dysfunction
|
PERISCOPE: Study Design
|
PERISCOPE: Change in PAV
|
MESA: Study Design
|
MESA: CVD and CHD Risk by CIMT or CAC Score
|
PREMIER: Percentage of All Participants With Hypertension (6 mo)
|
PREMIER: Percentage of All Participants With Optimal Blood Pressure (6 mo)
|
JNC 7: Classification and Management of Blood Pressure for Adults
|
PRINCE: Change in CRP Levels at 24 Weeks
|
PDAY: Percentage of Right Coronary Artery Intimal Surface Affected With Early Atherosclerosis
|
PDAY: Prevalence of lesions in LAD
|
PDAY: Prevalence of Risk Factors
|
PDAY: Prevalence of Lesions by Smoking and Non-HDL-C Status
|
Age-Adjusted Total Cholesterol Levels in NHANES III vs NHANES 1999-2000
|
NHANES I Epidemiologic Follow-up Study: CHD Incidence and Survival in African American Men and Women
|
Adult Population Not Reaching LDL-C Targets
|
Prevalence of Overweight in US Men: NHANES 1999-2000
|
Prevalence of Overweight in US Women: NHANES 1999-2000
|
Prevalence of Obesity in US Men: NHANES 1999-2000
|
Prevalence of Obesity in US Women: NHANES 1999-2000
|
Post-CABG: Impact of Aggressive vs Moderate Lowering of LDL-C on Atherosclerosis
|
Post-CABG Study: Aggressive vs Moderate Treatment
|
Post-CABG: End Points, Results, Conclusions
|
Post-CABG Angiographic Outcomes
|
Post-CABG: Event Rates by Cholesterol Group
|
Post-CABG: Aggressive LDL-C Lowering Delays Progression of Atherosclerosis in Women, Elderly, and Patients With Selected CHD Risk Factors
|
PROSPER: Primary Composite End Point Results CHD Death, Nonfatal MI, Fatal or Nonfatal Stroke
|
PROSPER: Secondary End Point Results
|
PROSPER: Rate of CHD-Related Death
|
Hypertriglyceridemia—An Independent Risk Factor for CHD: PROCAM Study
|
Fasting TG and Risk for CHD Death: Paris Prospective Study
|
CHD Mortality and Hyperinsulinemia: Paris Prospective Study (N=943)
|
Relation Between Baseline Fasting Insulin and Ischemic Heart Disease
|
NHANES III: Age-Adjusted Prevalence of Individual Risk Factors for the Metabolic Syndrome
|
NHANES III: Age-Adjusted Prevalence of >3 Risk Factors for the Metabolic Syndrome
|
NHANES III: Age-Specific Prevalence of the Metabolic Syndrome
|
Impact of Estrogen and Progestin on Cholesterol Concentrations
|
HRT Effects on C-Reactive Protein Levels: PEPI Trial Subgroup
|
MORE: Cardiovascular Events at 4-Year Follow-up
|
Prospective Pravastatin Pooling (PPP) Project: 112,000 Patient-Year Experience
|
MIRACL: Study Rationale
|
MIRACL: Study Design
|
MIRACL: Major Exclusion Criteria
|
MIRACL: Outcome Measures
|
MIRACL: Baseline Patient Characteristics
|
MIRACL: Change in Lipid Levels
|
MIRACL: Time to First Ischemic Event
|
MIRACL: Occurrence of Primary Combined End Point
|
MIRACL: Fatal or Nonfatal Stroke
|
MIRACL: Conclusions and Implications
|
PRISM: Event Rate Curves
|
REVERSAL: Effect of Moderate vs Intensive Statin Therapy
|
PROVE-IT: Median LDL-C Levels During Study
|
PROVE-IT: Primary Composite End Point
|
Post-CABG: Effect of Aggressive Lipid Lowering on a Subgroup of Patients With Diabetes
|
ORION: Study Design
|
ORION: Effects of Rosuvastatin on Change in Carotid Plaque Volume, Composition
|
PREDICT: Study Design
|
PREDICT: Primary Endpoint Event Rates in Successive Categories of CAC Score
|
PROVE-IT Substudy: Major Safety Outcomes
|
PROactive 10 Substudy: Time to First Event from MACE Endpointa
|
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
|
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
|
PROSPER: Association of Leptin With Diabetes
|
PROSPER: Association of Leptin With CVD
|
PROSPER: Association of Leptin With CVD
|
PROSPER: Association of Leptin With Diabetes
|
RECORD: Study Design
|
RECORD: CV Death and Hospitalization
|
RECORD: Time to Primary Endpoint
|
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
|
RECORD: Conclusion
|
NHANES: Gender Differences in Prevalence of Myocardial Infarction
|
NHANES: Gender Differences in Coronary Risk
|
Use of CAC Score for CHD Prediction: Design
|
S-Z
|
|
|
SANDS: Study Design
|
SANDS: Change in CIMT with Aggressive vs Standard Therapy
|
SHEEP: Risk Factors for Nonfatal MI in Men and Women
|
WISE: Prevalence of Angiographic CAD Based on BMI, Metabolic Status
|
Cholesterol and CHD: Seven Countries Study
|
Effect of Lifestyle Changes on Angiographic CAD
|
WOSCOPS: Effects of Lipid Lowering on Coronary Events in Primary Prevention Trial in Men
|
WOSCOPS: Relation of Baseline LDL-C to Event Rate
|
WOSCOPS: Relation of Baseline HDL-C to Event Rate
|
WOSCOPS: Relation Between Quintiles of LDL-C Reduction and CHD Events
|
WHI trial of Estrogen, Progestin Ended
|
Outcomes in WHI Trial of Estrogen, Progestin
|
WHI: CHD, Stroke Outcomes in Estrogen-Alone Arm
|
Treating to New Targets: Mean Lipid Levels
|
TNT: Hazard Ratios for the Primary Outcome
|
TNT: Hazard Ratios for Primary Outcome Components
|
TNT: Hazard Ratios for Secondary Outcomes
|
Relationship Between LDL-C and Event Rates in TNT and Other Statin Trials
|
TNT: Safety Profile
|
TROPHY: Analysis of New-Onset Hypertension
|
SPARCL Primary Outcome: Fatal or Nonfatal Stroke
|
Prevalence of Macrovascular Disease and CHD According to Quintiles of Fasting C-Peptide
|
Swedish Register Study Design and Baseline Characteristics
|
Swedish Register Study: Early Statin Treatment Improves Post-AMI Survival Rates
|
Swedish Register Study: Implications for Early Statin Treatment
|
STELLAR: Percent Change in LDL-C From Baseline
|
STELLAR: Percent Change in HDL-C From Baseline
|
STELLAR: Percent of Patients at NCEP ATP III LDL-C Goal (6-Week Data)
|
The Strong Heart Study: Differences in CVD Risk Factors by Diabetic Status in Men and Women
|
WESDR: Hyperglycemia and the Risk for Vascular Complications in Older-Onset Diabetes
|
WESDR: Hyperglycemia and the Risk for Cause-Specific CVD Mortality
|
UKPDS: Intensive Blood-Glucose vs Conventional Treatment in Patients With Type 2 Diabetes
|
UKPDS: Tight Blood Pressure Control vs Less Tight Control in Patients With Type 2 Diabetes
|
WOSCOPS: Development of Type 2 Diabetes
|
Strong Heart Study: Non–HDL-C as CVD Risk Predictor in Patients With Diabetes
|
Strong Heart Study: Non–HDL-C Compared With Other CVD Risk Predictors
|
Steno-2: Effect of Therapies on Selected Risk Factors
|
Steno-2 Study: Primary Composite End Point or Surgery for PAD
|
SEACOAST: Combination Therapy for Increased Non–HDL-C
Primary Endpoint
|
Women’s Health Study: Association of Fasting and Nonfasting Lipids With CVD
|
|
|
DIALOGUES IN DYSLIPIDEMIA
|
|
|
Case Study: Elderly Female
|
|
|
Case Study: Elderly Female
|
Case Study: Elderly Female
|
Case Study: Elderly Female
|
Case Study: Elderly Female
|
ATP III Framingham Risk Scoring: Assessing CHD Risk in Women
|
ATP III Framingham Risk Scoring: Female 20 Years Younger
|
ATP III: The Metabolic Syndrome
|
NHANES III: Age Specific Prevalence of the Metabolic Syndrome
|
Case Study: Elderly Female
|
Case Study: Elderly Female
|
Meta-Analysis: Overall Risk Reduction for Major Coronary Events by Age
|
HPS: Effects of Statins on First Major Vascular Event in Elderly
|
Meta-analysis: LDL-C Lowering on CVD Events (Including Stroke, Total Mortality)
|
HPS: Effect of Statins on Stroke Type
|
ASCOT-LLA: Stroke End Point
|
PROSPER: Stoke Outcomes According to Sex
|
Meta-Analysis: Cancer Incidence From Major Statin Trials
|
Polypharmacy and Aging
|
ATP III Considerations for Older Adults
|
Case Study: Male With Diabetes
|
|
|
Case Study: Male With Diabetes
|
Case Study: Male With Diabetes
|
Case Study: Male With Diabetes
|
ATP III Framingham Risk Scoring: Assessing CHD Risk in Men
|
ATP III: The Metabolic Syndrome
|
Relationship Between Type 2 Diabetes and the Metabolic Syndrome
|
ATP III: CHD Risk Equivalents
|
Case Study: Male With Diabetes
|
Time to Benefit of Smoking Cessation After Last Cigarette
|
Case Study: Male With Diabetes
|
Burden of Atherosclerosis in Type 2 Diabetes
|
What's New for High Risk Patients?
|
Case Study: Male With Diabetes
|
CHD Prevention Trials With Statins in Diabetes Subjects: Subgroup Analysis
|
HPS Substudy: First Major Coronary Event and Stroke by Prior Diabetes Status
|
CARDS: Cumulative Hazard for Primary Endpoint
|
CARDS: Median Lipid Levels
|
HOT Trial: Effect of BP Therapy on CVD Events in Diabetes
|
UKPDS: MI and Microvascular End Points Associated With Hyperglycemia
|
NHANES III: Prevalence of Metabolic Syndrome
|
Diabetes Prevention Program (DPP): Reduction in Diabetes Incidence
|
DPP: Diabetes Incidence Rates by Ethnicity
|
Steno-2 Study: Percentage of Patients Reaching Intensive Treatment Goals
|
Steno-2 Study: Composite Endpoint
|
Steno-2 Study: Microvascular End Points
|
ADA: Dyslipidemia Management in Adults With Diabetes
|
Case Study: Male With Hypertension
|
|
|
Case Study: Male With Hypertension
|
Case Study: Male With Hypertension
|
Case Study: Male With Hypertension
|
ATP III Framingham Risk Scoring: Assessing CHD Risk in Men
|
ATP III: The Metabolic Syndrome (Diagnosis is established when >3 risk factors are present)
|
Case Study: Male With Hypertension
|
Case Study: Male With Hypertension
|
ASCOT-LLA: Study Design
|
ASCOT-LLA: BP, Lipid Results
|
ASCOT-LLA: Primary End Point in Subgroups
|
ASCOT-LLA: Secondary End Points
|
ALLHAT-LLT: Study Design
|
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
|
Clinical Trial Evidence of TG, HDL-C, LDL-C Change With Fibrates
|
Recombinant ApoA-I Milano: Change in Atheroma Volume as Measured by IVUS
|
Recombinant ApoA-I Milano: Atheroma Regression With High-Dose Therapy
|
Heart Protection Study (HPS): Study Design
|
HPS: Major Vascular Event by HDL-C and TG
|
ATP III: Improving Adherence—Focus on the Patient
|
ATP III: Improving Adherence—Focus on Physician, Delivery System
|
Case Study: Postmenopausal Female
|
|
|
Case Study: Postmenopausal Female
|
Case Study: Postmenopausal Female
|
Case Study: Postmenopausal Female
|
Case Study: Postmenopausal Female
|
ATP III Framingham Risk Scoring: Assessing CHD Risk in Women
|
Leading Causes of Death for US Females, 2001
|
ATP III: The Metabolic Syndrome
|
Case Study: Postmenopausal Female
|
Case Study: Postmenopausal Female
|
Meta-Analysis: Overall Risk Reduction for Major Coronary Events by Sex
|
Heart Protection Study (HPS): First Major Vascular Event by Sex
|
Heart and Estrogen/progestin Replacement Study (HERS): Primary CHD Events
|
Women's Health Initiative (WHI) Primary CHD Events
|
WHI Outcomes: Estrogen + Progestin
|
WHI Outcomes: Estrogen Alone
|
FDA's Labeling for HRT in Women
|
AHA/CDC Panel: Recommendations for Use of hs-CRP in Clinical Practice
|
AHA/CDC Panel: Recommendations for hs-CRP Laboratory Testing
|
Assessment of the Clinical Utility of Novel Markers for CV Risk
|
AHA Evidence-Based 2004 Guidelines for CVD Prevention in Women
|
AHA Evidence-Based 2004 Guidelines for CVD Prevention in Women (cont'd)
|
AHA Evidence-Based 2004 Guidelines for CVD Prevention in Women (cont'd)
|
A Wake-Up Call
|
Didactic: State-of-the-Art Evidence for Lipid Intervention
|
|
|
Number of Potential Candidates for Lifestyle, Drug Therapies
|
Prevalence of US Population With Elevated Total Cholesterol, LDL-C
|
L-TAP/NHANES III: Adult Population Not Reaching LDL-C Goals
|
L-TAP: Patient Success in Achieving LDL-C Goals
|
ATP III: Updated LDL-C Goals, Treatment Cutpoints
|
High-Risk Patients
|
ATP III: Updated LDL-C Goals Treatment Cutpoints
|
ATP III: Treatment of Postmenopausal Women and Elderly
|
ATP III: Management of Diabetic Dyslipidemia
|
JNC 7: Treatment Algorithm for Hypertension
|
HPS: Effects of Simvastatin on Cause Specific Mortality
|
REVERSAL: Effect of Moderate vs Intensive Statin Therapy
|
PROVE-IT Primary Composite End Point
|
A TO Z Trial: Estimates of Rates of Primary End Point
|
CARDS: Effect of Treatment on Primary and Secondary End Points
|
CARDS: Major CVD Events
|
Clinical Lessons Learned From Recent Trials
|
Looking Ahead to Future Clinical Trials
|
Framingham Risk Scoring
|
Nutritional Components of the Therapeutic Lifestyle Changes (TLC) Diet
|
Meta-Analysis: Effects of Aerobic Exercise on Lipids
|
Benefits of Modest Weight Loss in the Overweight and Obese
|
Meta-Analysis: CHD Incidence by Class of Intervention
|
Efficacy of Drugs Affecting Lipoprotein Metabolism
|
Possible Side Effects of Drugs Affecting Lipoprotein Metabolism
|
Lessons Learned
|
|
|
MANAGING ATHEROGENIC DYSLIPIDEMIA
|
|
|
Didactic
|
|
|
Atherogenic Dyslipidemia in Obesity, Insulin Resistance, MetSyn
|
Residual Cardiovascular Risk in Major Statin Trials
|
TGs and CHD Risk: Meta-Analysis of 29 Studies in Western Populations
|
Association of TG Levels and Incident CVD According to Fasting Status
|
Risk for MI, IHD, and Total Death by Nonfasting TG Increases
|
TG Level Remains A CVD Risk Factor Among Statin-Treated Patients
|
Non–HDL-C and CVD Risk
|
CHD Risk: HDL-C Versus LDL-C as Predictor
|
Statin Therapy Does Not Eliminate CVD Risk Associated With Low HDL-C
|
Underestimation of Number of LDL Particles With Increased Small LDL
|
TRIMS: Increased LDL Particle Size With Fenofibrate in HyperTG Patients Is Associated With End-of-Treatment TG
|
Look AHEAD: Improvement in Metabolic Syndrome Components at 1 Year
|
Pharmacologic Options for Managing Atherogenic Dyslipidemia
|
Coronary Drug Project: Niacin Effects on CVD, Mortality
|
HHS: Primary Prevention With Gemfibrozil
|
VA-HIT: Effect of Gemfibrozil on Primary Endpoint, Lipids
|
VA-HIT: LDL, HDL Particle Numbers Are Significant, Independent Predictors of New CHD Events
|
MI Prevention With Bezafibrate in Metabolic Syndrome
|
FIELD: End of Study Lipid Results
|
FIELD: Primary and Secondary Endpoints
|
Omega-3 Acid Ethyl Esters: Secondary-Prevention Studies
|
GISSI-Prevenzione: Time Course of Clinical Events
|
Omega-3 Acid Ethyl Esters: Lipid Effects in Patients with TG>500 mg/dL
|
Pharmacologic Options for Managing Atherogenic Dyslipidemia
|
SAFARI: Combination Therapy in Patients With Combined Hyperlipidemia
|
SAFARI: Effects on LDL Particle Subclasses
|
Atorvastatin and Fenofibrate Alone or in Combination in Patients With Type 2 Diabetes
|
Statin-Fibrate Combination Therapy: Pharmacokinetic Interactions
|
Lovastatin ± Niacin: Lipid Effects
|
HATS: Angiographic and Clinical Endpoints After 3 Years
|
ARBITER 2: Statin-Placebo Versus Statin-Niacin (1 of 2)
|
ARBITER 2: Statin-Placebo Versus Statin-Niacin (2 of 2)
|
Omega-3 Acid Ethyl Esters in Combination With Atorvastatin
|
Omega-3 Acid Ethyl Esters and Simvastatin in Patients With Combined Hyperlipidemia
|
COMBOS: Omega-3 Acid Ethyl Esters and Simvastatin in Patients with High TGs
|
JELIS: Incidence of Coronary Events
|
ATP III: Management of Elevated TG
|
Conclusions
|
Case Study
|
|
|
Patient Presentation
|
Initial Lab Values
|
What the Evidence Says
|
Treatment Recommendation
|
3-Month Follow-Up
|
Treatment Considerations
|
2-Month Follow-up
|
What the Evidence Says
|
What the Evidence Says (cont’d)
|
Treatment Recommendation
|
What the Evidence Says
|
Treatment Recommendation
|
What the Evidence Says
|
AHA Scientific Statement on Omega-3 Acid Ethyl Esters Intake
|
Conclusion
|
|
|
NONPHARMACOLOGIC THERAPIES
|
|
|
Diet
|
|
|
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
|
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
|
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
|
Diabetes Prevention Program: Study Design
|
Diabetes Prevention Program
|
AVERT: Overview of Study Procedures
|
L-TAP: Patient Success in Achieving Target LDL-C Levels
|
Lyon Diet Heart Study: Cumulative Survival Without Cardiac Death and Nonfatal MI
|
Effect of Lifestyle Changes on Angiographic CAD
|
Outcomes in WHI Trial of Estrogen, Progestin
|
Trans-Fatty Acid Intake and Relative Risk for CHD
|
Lipid Lowering and Plaque Regression: Monotherapy Studies
|
Event Reduction in Angiographic Plaque Regression Trials
|
Effect of Cholesterol Lowering on Myocardial Ischemia
|
Angiographically Inapparent Atheroma
|
ATP III: Features Shared With ATP II
|
ATP III: Nutritional Components of the TLC Diet
|
ATP III: Additional Dietary Options for LDL-C Lowering
|
ATP III: Management of Elevated TG
|
Statin Advisory: Risk Factors for Statin-Associated Myopathy
|
ABCs of CVD Risk Management (cont.)
|
Two LC-HP Diets Compared With Conventional Recommendations
|
LC-HP Diets: Potential Adverse Effects
|
Low-Carb vs Low-Fat Diet in Obese Patients (1 Y)
|
Low-Carb vs Low-Fat Diet in Overweight Patients (24 wk)
|
Potential Mortality Reduction With Lifestyle/Dietary Changes
|
Fruit/Vegetable Consumption: Effects on Stroke Risk Reduction
|
Reduced Intake of Trans-Fatty Acids: Estimated Effects on CHD
|
Effects of Drug Therapy and Diet on Lipids
|
Wine Consumption and CHD
|
Impact on TG Following Dietary Restrictions
|
TG Metabolism in CHD: Studies in the Postprandial State
|
Nonpharmacological Approaches to TG Lowering
|
Benefits of Intensive Lifestyle Changes on TG Levels
|
Effects of Lipid Lowering on Endothelial Function: Hypercholesterolemic Patients
|
Effects of Lipid-Lowering Therapy on Myocardial Perfusion in CHD Patients
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Results
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Additional Results at Year 1
|
Effects of ↑ HDL-C and ↓ LDL-C on First Acute Major Coronary Events: Design
|
Exercise
|
|
|
Finnish Diabetes Prevention Study: Treating the IGT Patient With Lifestyle Changes
|
Finnish Diabetes Prevention Study: Success in Achieving Treatment Goals at 1 Year
|
Finnish Diabetes Prevention Study: Reduction in Risk for Diabetes
|
Diabetes Prevention Program: Study Design
|
Diabetes Prevention Program
|
Effect of Lifestyle Changes on Angiographic CAD
|
Treatment Options for Peripheral Arterial Disease
|
Treatment Options for Peripheral Arterial Disease (cont)
|
Lipid Lowering and Plaque Regression: Monotherapy Studies
|
Angiographically Inapparent Atheroma
|
ATP III: Features Shared With ATP II
|
ATP III: Management of Elevated TG
|
ABCs of CVD Risk Management (cont.)
|
Potential Mortality Reduction With Lifestyle/Dietary Changes
|
Effects of Drug Therapy and Diet on Lipids
|
Nonpharmacological Approaches to TG Lowering
|
Benefits of Intensive Lifestyle Changes on TG Levels
|
Prevalence and CVD Correlates of Low Cardiorespiratory Fitness
|
Metabolic Syndrome and Cardiorespiratory Fitness
|
Other
|
|
|
AVERT: Study Design and Inclusion Criteria
|
AVERT: Major Exclusion Criteria
|
AVERT: Overview of Study Procedures
|
AVERT: Primary Efficacy Assessment
|
AVERT: Secondary Efficacy Assessments
|
AVERT: Baseline Patient Characteristics
|
AVERT: Ischemic Events
|
AVERT: Time to First Ischemic Event
|
AVERT: Summary of Lipid Parameters
|
AVERT: Incidence of First Ischemic Event by Time
|
AVERT: Safety Evaluation
|
AVERT: Conclusions
|
Heart Protection Study (HPS): Elibigility
|
HPS: Design and Interventions
|
Heart Protection Study (HPS): End Points for Antioxidant Vitamin Supplementation
|
HPS: Effects of Antioxidant Vitamins on Cause-Specific Mortality
|
HPS: Effects of Antioxidant Vitamins on First Major Vascular Event
|
HPS: Effects of Antioxidant Vitamins on Vascular Events by Year
|
HPS: Effects of Antioxidant Vitamins on Vascular Events by LDL-C
|
HATS: Lipid Levels Before and During Treatment
|
HATS: Percent Change in Stenosis
|
JNC 7: Classification and Management of Blood Pressure for Adults
|
Treatment Options for Peripheral Arterial Disease
|
ABCs of CVD Risk Management (cont.)
|
Nonpharmacological Approaches to TG Lowering
|
Intensive Lifestyle Interventions: Effects on Endothelial Function and Inflammatory Markers Design
|
Intensive Lifestyle Interventions: Effects on Endothelial Function and Inflammatory Markers Results
|
|
|
PHARMACOLOGIC THERAPIES: BLOOD PRESSURE MANAGEMENT
|
|
|
Blood Pressure Management
|
|
|
Case Study: Elderly Female
|
ALLHAT-LLT: All-Cause Mortality
|
ALLHAT-LLT: Comparison to Other Large, Long-Term Statin Trials
|
ASCOT–LLA: Study Design
|
ASCOT-LLA: Primary End Point
|
ASCOT-LLA: Primary End Point in Subgroups
|
ACCORD BP: Effects of Intensive BP_Control on Type 2 Diabetes
|
Primary CHD Prevention in Patients With Type 2 Diabetes: The Helsinki Heart Study
|
TROPHY: Analysis of New-Onset Hypertension
|
UKPDS: Tight Blood Pressure Control vs Less Tight Control in Patients With Type 2 Diabetes
|
Angiographically Inapparent Atheroma
|
JNC 7: Treatment Algorithm for Hypertension
|
ABCs of CVD Risk Management
|
HF Rates in Hypersensitive Blacks and Non-Blacks: ALLHAT
|
Safety and Tolerability of Monotherapy, Combination BP Therapy
|
ASCOT-LLA: Incidence for Total CVD Events/Procedures in Patients With Diabetes
|
Common Drug Treatments for Patients With Metabolic Syndrome
|
Effect of Monotherapy, Combination Therapy on Blood Pressures
|
Renin-Angiotensin Blockade: Beyond BP Lowering
|
CLINICAL TRIALS: A-F
|
A-HeFT: First HF Trial in African-Americans
|
A-HeFT: 43% Decrease in Mortality
|
A-HeFT: Components of Composite Score
|
A-HeFT: Conclusions
|
AASK: Relative Risk Reduction With Ramipril vs Amlodipine
|
AASK: Renoprotective Effects of Ramipril in Hypertension
|
ADHERE: Long-Term Medication Use
|
ALLHAT: Design, Hypothesis, and Baseline Demographics
|
ALLHAT: Blood Pressure Results by Treatment Group
|
ALLHAT: Cumulative Event Rates for Primary Outcome
|
ALLHAT: Cumulative Event Rates for Heart Failure
|
ALLHAT: Lisinopril vs Chlorthalidone in Blacks
|
ALLHAT: Lisinopril vs Chlorthalidone in Nonblacks
|
ALLHAT: Amlodipine vs Chlorthalidone in Blacks
|
ALLHAT: Amlodipine vs Chlorthalidone in Nonblacks
|
ALLHAT: Heart Failure Rate for Blacks
|
ALLHAT: Heart Failure Rate for Nonblacks
|
ALLHAT: Angioedema in Blacks vs Nonblacks
|
ALLHAT: Effect of Antihypertensive Class on New-Onset Diabetes
|
ALLHAT: Fasting Glucose by Treatment Group
|
ALLHAT: Reduced Diabetes Risk With Lisinopril
|
BP-Lowering Treatment Trialists: Heart Failure
|
CALM: Renoprotection With Candesartan vs Lisinopril in Type 2 Diabetes
|
CAMELOT: Design, Hypothesis, and Baseline Characteristics
|
CAMELOT: Primary Endpoint (1 of 2)
|
CAMELOT: Primary Endpoint (2 of 2)
|
CHARM: ARBs in Heart Failure
|
CHARM-Overall: Design, Hypothesis, and Baseline Characteristics
|
CHARM-Overall: Primary Endpoint (CV and Non-CV Death)
|
CHARM-Alternative: Primary Endpoint
|
DECODE: IFG and IGT Are Associated With Increased Mortality Rate
|
DPP: Study Design
|
DPP: Incidence of Type 2 Diabetes
|
DPP: Fasting Plasma Glucose Over Time
|
East-West Study: 7-Year Incidence of Fatal and Nonfatal MI in Type 2 Diabetes and CHD
|
EPHESUS: Death Rate From CV Causes or Hospitalization for CV Events
|
EUROPA: Design, Hypothesis, and Baseline Demographics
|